Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis

Egil Røsjø; Kjell-Morten Myhr; Kristin I Løken-Amsrud; Søren J Bakke; Antonie G Beiske; Kristian S Bjerve; Harald Hovdal; Finn Lilleås; Rune Midgard; Tom Pedersen; Jūratė Šaltytė Benth; Øivind Torkildsen; Stig Wergeland; Annika E Michelsen; Pål Aukrust; Thor Ueland; Trygve Holmøy

doi:10.1016/j.jneuroim.2015.02.001

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis

J Neuroimmunol. 2015 Mar 15:280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.

Authors

Egil Røsjø¹, Kjell-Morten Myhr², Kristin I Løken-Amsrud³, Søren J Bakke⁴, Antonie G Beiske⁵, Kristian S Bjerve⁶, Harald Hovdal⁷, Finn Lilleås⁸, Rune Midgard⁹, Tom Pedersen¹⁰, Jūratė Šaltytė Benth¹¹, Øivind Torkildsen¹², Stig Wergeland¹³, Annika E Michelsen¹⁴, Pål Aukrust¹⁵, Thor Ueland¹⁴, Trygve Holmøy¹⁶

Affiliations

¹ Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. Electronic address: egil.rorvik.rosjo@ahus.no.
² Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; KG Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
³ Department of Neurology, Innlandet Hospital Trust, Lillehammer, Norway.
⁴ Department of Neuroradiology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
⁵ Multiple Sclerosis Centre Hakadal, Hakadal, Norway.
⁶ Clinic of Laboratory Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway; Department of Laboratory Medicine, Children's and Women's Health, Norwegian University of Science and Technology, Trondheim, Norway.
⁷ Department of Neurology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
⁸ Curato Oslo, Oslo, Norway.
⁹ Department of Neurology, Molde Hospital, Molde, Norway; Unit for Applied Clinical Research, Norwegian University of Science and Technology, Trondheim, Norway.
¹⁰ Unilabs Drammen, Drammen, Norway.
¹¹ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Helse Sør-Øst Health Services Research Centre, Akershus University Hospital, Lørenskog, Norway.
¹² KG Jebsen MS Research Centre, Department of Clinical Medicine, University of Bergen, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
¹³ Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
¹⁴ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway.
¹⁵ Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Section for Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, Oslo, Norway; KG Jebsen Inflammatory Research Center, University of Oslo, Oslo, Norway.
¹⁶ Department of Neurology, Akershus University Hospital, Lørenskog, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

PMID: 25773151
DOI: 10.1016/j.jneuroim.2015.02.001

Abstract

To explore if vitamin D modulates interferon-β1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-β1a treatment effects.

Keywords: Interferon-β treatment; Relapsing-remitting multiple sclerosis; Vitamin D.

MeSH terms

Adjuvants, Immunologic / therapeutic use*
Adolescent
Adult
Cytokines / blood
Female
Humans
Interferon beta-1a
Interferon-beta / therapeutic use*
Longitudinal Studies
Magnetic Resonance Imaging*
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting* / blood
Multiple Sclerosis, Relapsing-Remitting* / drug therapy
Multiple Sclerosis, Relapsing-Remitting* / pathology
Norway
Regression Analysis
Retrospective Studies
Time Factors
Vitamin D / blood*
Young Adult

Substances

Adjuvants, Immunologic
Cytokines
Vitamin D
Interferon-beta
Interferon beta-1a